English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Apha-1-adrenergic receptor antagonists (α 1 -blockers) can suppress pro-inflammatory cytokines, thereby potentially improving outcomes among patients with COVID-19. Accordingly, we evaluated the association between α 1 -blocker exposure (before or during hospitalization) and COVID-19 in-hospital mortality. We identified 2,627 men aged 45 or older who were admitted to Mount Sinai hospitals with COVID-19 between February 24 and May 31, 2020, in New York. Men exposed to α 1 -blockers ( N  = 436) were older (median age 73 vs. 64 years,  P  &amp;lt; 0.001) and more likely to have comorbidities than unexposed men ( N  = 2,191). Overall, 777 (29.6%) patients died in hospital, and 1,850 (70.4%) were discharged. Notably, we found that α 1 -blocker exposure was independently associated with improved in-hospital mortality in a multivariable logistic analysis (OR 0.699; 95% CI, 0.498-0.982;  P  = 0.039) after adjusting for patient demographics, comorbidities, and baseline vitals and labs. The protective effect of α 1 -blockers was stronger among patients with documented inpatient exposure to α 1 -blockers (OR 0.624; 95% CI 0.431-0.903;  P  = 0.012). Finally, age-stratified analyses suggested variable benefit from inpatient α 1 -blocker across age groups: Age 45-65 OR 0.483, 95% CI 0.216-1.081 ( P  = 0.077); Age 55-75 OR 0.535, 95% CI 0.323-0.885 ( P  = 0.015); Age 65-89 OR 0.727, 95% CI 0.484-1.092 ( P  = 0.124). Taken together, clinical trials to assess the therapeutic value of α 1 -blockers for COVID-19 complications are warranted.

Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients